NCT02054702View on ClinicalTrials.gov

Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Acute Schizophrenia

PHASE3CompletedINTERVENTIONAL
Enrollment

97

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

June 30, 2014

Study Completion Date

July 31, 2014

Conditions
Schizophrenia
Interventions
DRUG

Brexpiprazole

Treatment (6 weeks) Up to 4 mg/day, once daily dose, tablets, orally

DRUG

Aripiprazole

Up to 20 mg/day, once daily dose, tablets, orally

Sponsors
All Listed Sponsors
collaborator

Otsuka Pharmaceutical Co., Ltd.

INDUSTRY

lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY